A Look At GR Life Style (SEHK:108) Valuation After AI Healthcare Cooperation With Mingzhi Medical Technology
Make better investment decisions with Simply Wall St’s easy, visual tools that give you a competitive edge.
GR Life Style (SEHK:108) has signed a cooperation memorandum with Mingzhi Medical Technology to pursue AI driven oncology research and traditional Chinese medicine projects, as well as new digital health management and clinical trial platforms.
See our latest analysis for GR Life Style.
At a share price of HK$2.59, GR Life Style has had a mixed shorter term pattern, with a 1 day share price return of 1.17% and a 7 day share price return of negative 15.08%, while its 30 day and 90 day share price returns of 9.75% and 32.14% respectively sit against a very large 1 year total shareholder return of about 2.5x. This suggests recent momentum has cooled slightly after a strong run as investors weigh the AI powered healthcare pivot and earlier property focused repositioning.
If this shift toward AI powered healthcare services has caught your interest, it could be a good moment to look at healthcare stocks as you compare other potential opportunities in the sector.
So with GR Life Style reporting a recent loss and an intrinsic value estimate that sits above its HK$2.59 share price, is the AI powered healthcare pivot creating a genuine entry point, or is the market already pricing in future growth?
On the numbers we have, GR Life Style trades on a P/S of 27.6x, far above both peers and the wider Hong Kong real estate sector. The last close sits at HK$2.59.
The P/S multiple compares the company’s share price to its revenue, so a higher figure usually reflects investors placing a richer value on each dollar of sales. For a business that is currently loss making, with earnings declining by 69.6% per year over the past 5 years and a Return on Equity of 41.94% in the red, such a premium signals that the market is placing a lot of weight on future potential rather than current profitability.
Against that backdrop, GR Life Style’s P/S of 27.6x stands in sharp contrast to the Hong Kong real estate industry average of 0.7x and a peer average of 2.1x. That is a steep gap for a company that is unprofitable, has no clear revenue or earnings forecasts available, and is trading above the SWS DCF estimate of future cash flow value of HK$0.11. This suggests expectations for the AI powered healthcare pivot are already embedded into the price rather than being a hidden story.
See what the numbers say about this price — find out in our valuation breakdown.
Result: Price-to-Sales of 27.6x (OVERVALUED)
However, you also need to factor in the company’s HK$916.692 million loss, as well as the tension between its AI story and its core property focused business model.
link
